Recent changes in endometrial cancer trends among menopausal-age US women.
Open accessAbstract
Background Changes in endometrial cancer incidence rates after the precipitous decline in menopausal hormone therapy (MHT) use in 2002 have not been evaluated.Methods Using data from the Surveillance, Epidemiology, and End Results Program from 1992 to 2009 (SEER 13), we identified 63428 incident endometrial cancer cases among women ages 20-74. We compared annual percent change (APC) in endometrial cancer incidence rates from 1992 to 2002 to rates from 2003 to 2009.Results In contrast to the constant endometrial cancer rate pattern observed from 1992 to 2002 (APC 0.0%), rates increased after 2002 in women 50-74 years old (2.5%; PAPC comparison<0.01). Endometrial cancer incidence increased over the entire time period among women ages 20-49 (1992-2002: 1.1%; 2003-2009: 2.1%; PAPC comparison=0.21). Post-2002 increases in incidence among women ages 50-74 were specific to Type I endometrial tumors (1992-2002: -0.6%; 2003-2009: 1.6%; PAPC comparison<0.01).Discussion The increase in endometrial cancer incidence rates after 2002 may be related to the widespread decrease in estrogen plus progestin MHT use, which has been reported to lower endometrial cancer risk in overweight and obese women.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 17 · Cited by 98
- Authors
- Wartko, P., Sherman, M. E., Yang, H. P., Felix, A. S., Brinton, L. A., & Trabert, B.
- Affiliations
- National Cancer Institute (US)
- Corresponding author
- Trabert, Britton
- Venue
- Cancer Epidemiology
- Publisher
- Elsevier BV
- Published
- 2013-08
- Volume
- 37
- Issue
- 4
- Pages
- 374-377
- ISSN
- 1877-7821 (ISSN-L)
- PMC
- PMC3679300
- OpenAlex
- W2070921386
- Cited by
- 98
- References
- 17
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 4 · 2023: 5 · 2022: 6 · 2021: 8 · 2020: 6 · 2019: 13 · 2018: 9 · 2017: 12 · 2016: 11 · 2015: 4 · 2014: 8 · 2013: 2 · 2012: 1
- FWCI
- 9.35
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Epidemiology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (Z01CP010126)
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
- Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- endometrial cancer, incidence trends, hormone replacement therapy, estrogen plus progestin, postmenopausal women, obesity, overweight, cancer risk
- MeSH terms
- Adult, Age Factors, Aged, Female, Humans, Menopause, Middle Aged, Obesity, Time Factors, United States, Estrogen Replacement Therapy, Incidence, Endometrial Neoplasms, SEER Program, Overweight, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review